Related medicinesRusfertide

Where it comes from

Made in
Hepatocytes of the liver
Sent out by
Rising iron stores and inflammation (interleukin-6) push it up; the need for new red cells, signalled by erythroferrone, pulls it down
Acts on
  • The gut lining cells that absorb iron
  • The macrophages that recycle iron
  • The liver cells that store iron

What it does

  • Locks iron inside cells and out of the blood
  • Explains the anaemia of chronic disease: inflammation raises hepcidin and starves red cells of iron 1
  • Too little of it, as in hereditary haemochromatosis, lets iron overload the organs

In medicine

  • Rusfertide, a hepcidin mimetic, is approved in the United States (2026) for polycythaemia vera, to curb the excess of red cells 3
  • Hepcidin blood tests are used in research to tell iron deficiency from inflammation 1
  • The Iron Metabolism area of the Evigenics report reads HFE, the gene upstream of hepcidin

Beyond the body’s own use

  • Rusfertide, injected weekly, cut the need for blood removal in the 293-patient phase 3 VERIFY trial: 77% of those treated needed no phlebotomy against 33% on placebo, and fewer than half as many were still above a haematocrit of 45% 2
  • Blocking hepcidin is the opposite bet, tried for the anaemia of chronic disease and of kidney disease, where too much of it starves red cells of iron; nothing in that line is approved
  • The hepcidin blood test remains mainly a research measure, because the assays do not agree well enough to set a reference range 1; ferritin and transferrin saturation are still the clinical measures of iron

Sources

  1. Girelli et al., Hepcidin in the diagnosis of iron disorders, Blood 2016
  2. Kuykendall et al., Rusfertide versus placebo in polycythaemia vera (VERIFY), Journal of Clinical Oncology 2026
  3. Rusfertide (Mimrylo), FDA application NDA 220605

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.